544 related articles for article (PubMed ID: 19848448)
1. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
2. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
[TBL] [Abstract][Full Text] [Related]
3. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.
Berger M; Ablasser A; Kim S; Bekeredjian-Ding I; Giese T; Endres S; Hornung V; Hartmann G
J Immunother; 2009 Apr; 32(3):262-71. PubMed ID: 19242374
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7.
Bourquin C; Schmidt L; Lanz AL; Storch B; Wurzenberger C; Anz D; Sandholzer N; Mocikat R; Berger M; Poeck H; Hartmann G; Hornung V; Endres S
J Immunol; 2009 Nov; 183(10):6078-86. PubMed ID: 19890064
[TBL] [Abstract][Full Text] [Related]
5. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation.
Larangé A; Antonios D; Pallardy M; Kerdine-Römer S
J Leukoc Biol; 2009 Apr; 85(4):673-83. PubMed ID: 19164127
[TBL] [Abstract][Full Text] [Related]
6. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
[TBL] [Abstract][Full Text] [Related]
7. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells.
Lombardi V; Van Overtvelt L; Horiot S; Moingeon P
J Immunol; 2009 Mar; 182(6):3372-9. PubMed ID: 19265114
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
[TBL] [Abstract][Full Text] [Related]
9. Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8.
Janke M; Poth J; Wimmenauer V; Giese T; Coch C; Barchet W; Schlee M; Hartmann G
J Allergy Clin Immunol; 2009 May; 123(5):1026-33. PubMed ID: 19361845
[TBL] [Abstract][Full Text] [Related]
10. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
[TBL] [Abstract][Full Text] [Related]
11. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
12. Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells along the myeloid lineage.
Sioud M; Fløisand Y; Forfang L; Lund-Johansen F
J Mol Biol; 2006 Dec; 364(5):945-54. PubMed ID: 17049554
[TBL] [Abstract][Full Text] [Related]
13. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H
Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
[TBL] [Abstract][Full Text] [Related]
15. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells.
Hurst J; Prinz N; Lorenz M; Bauer S; Chapman J; Lackner KJ; von Landenberg P
Immunobiology; 2009; 214(8):683-91. PubMed ID: 19249118
[TBL] [Abstract][Full Text] [Related]
16. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways.
Sawaki J; Tsutsui H; Hayashi N; Yasuda K; Akira S; Tanizawa T; Nakanishi K
Int Immunol; 2007 Mar; 19(3):311-20. PubMed ID: 17289654
[TBL] [Abstract][Full Text] [Related]
17. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides.
Jurk M; Kritzler A; Schulte B; Tluk S; Schetter C; Krieg AM; Vollmer J
Eur J Immunol; 2006 Jul; 36(7):1815-26. PubMed ID: 16783850
[TBL] [Abstract][Full Text] [Related]
18. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
[TBL] [Abstract][Full Text] [Related]
19. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
Hackstein H; Knoche A; Nockher A; Poeling J; Kubin T; Jurk M; Vollmer J; Bein G
Cell Immunol; 2011; 271(2):401-12. PubMed ID: 21889130
[TBL] [Abstract][Full Text] [Related]
20. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]